Bristol-Myers Squibb’s (BMS) Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) Receives EU Approval for 1L Intermediate- and Poor-Risk Advanced RCC

 Bristol-Myers Squibb’s (BMS) Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) Receives EU Approval for 1L Intermediate- and Poor-Risk Advanced RCC

Bristol-Myers Squibb’s (BMS) Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) Receives EU Approval for 1L Intermediate- and Poor-Risk Advanced RCC

Shots:
  • The approval is based on P-III CheckMate-214 study results assessing Opdivo (3mg/kg) + low-dose Yervoy(1mg/kg) vs sunitinib (50mg, qd) in patients with previously untreated advance RCC
  • P-III Checkmate-214 study results: ORR (41.6% vs 26.5%); CRR (9.4% vs 1.2%); Grade 3 or 4 adverse events (65% vs 76%)
  • Opdivo (nivolumab) is a programmed death-1 (PD-1) immune checkpoint inhibitor targeted for cancer cells, and is approved in 65 countries including the US, EU, Japan, China
Click here to read full press release/ article | Ref: Bristol-Myers Squibb | Image: Bull City Lawyer

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post